Diagnostics Department, Asahi Kasei Pharma Corporation, Tokyo, Japan.
Mol Diagn Ther. 2010 Feb 1;14(1):49-51. doi: 10.1007/BF03256353.
Diabetes mellitus is a worldwide healthcare issue, with the number of diabetic patients continuing to increase. Strict control of plasma glucose levels is critical in order to avoid the potentially severe complications of diabetes, making tests for monitoring of glycemic control essential in the management of the disease. Glycated hemoglobin (HbA(1c)) measurement is currently the most commonly used test to monitor glycemic control in patients with diabetes. Based on the results of the Diabetes Control and Complications Trial (DCCT), an HbA(1c) level of <7% has been recommended to prevent the onset and progression of chronic diabetic complications. However, HbA(1c) may not be suitable for evaluating short-term variations in glycemic control, because of the long lifespan of erythrocytes (120 days). Glycated albumin (GA) is an indicator of diabetes that is more sensitive to change in plasma glucose than HbA(1c). Lucica GA-L is a new diagnostic test for measuring GA. The test is based on an enzymatic method that uses liquid reagents requiring no preparation. Measuring the GA level should provide useful information on glycemic control when monitoring effects of therapy for patients with gestational diabetes, unstable plasma glucose levels, variant hemoglobins or diseases that shorten the lifespan of erythrocytes.
糖尿病是一个全球性的医疗保健问题，糖尿病患者的数量持续增加。为了避免糖尿病的潜在严重并发症，严格控制血浆葡萄糖水平至关重要，因此监测血糖控制对于疾病的管理至关重要。糖化血红蛋白（HbA1c）测量目前是监测糖尿病患者血糖控制最常用的测试。基于糖尿病控制和并发症试验（DCCT）的结果，建议将 HbA1c 水平控制在<7%以下，以预防慢性糖尿病并发症的发生和进展。然而，HbA1c 可能不适合评估血糖控制的短期变化，因为红细胞的寿命较长（120 天）。糖化白蛋白（GA）是一种比 HbA1c 更能敏感反映血糖变化的糖尿病指标。Lucica GA-L 是一种新的用于测量 GA 的诊断测试。该测试基于一种使用无需准备的液体试剂的酶促方法。当监测妊娠糖尿病、不稳定的血糖水平、变异血红蛋白或缩短红细胞寿命的疾病患者的治疗效果时，测量 GA 水平应该可以提供有关血糖控制的有用信息。
